Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $49.98 USD
Change Today +0.12 / 0.24%
Volume 390.4K
IPXL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

30831 Huntwood Avenue

Hayward, CA 94544

United States

Phone: 510-476-2000

Fax: 510-240-6096

Impax Laboratories, Inc., a technology-based, specialty pharmaceutical company, engages in the development, manufacture, and marketing of bioequivalent pharmaceutical products; and development and marketing of branded products. The company also provides research and development services to unrelated third-party pharmaceutical entities. Segments The company operates in two segments, Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceuticals Division (Impax Division). Global Division The Global division focuses on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established nonproprietary drug names rather than by a brand name. In the generic pharmaceutical market, the company focuses its efforts on developing, manufacturing, selling and distributing controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. The company’s Global Division also generates revenues from research and development services provided under a joint development agreement with an unrelated third-party pharmaceutical entity. In addition to its focus on solid oral dosage products, it has expanded its generic pharmaceutical products portfolio to include alternative dosage form products, primarily through alliance and collaboration agreements with third parties, such as its development, supply and distribution agreement with TOLMAR, Inc. (Tolmar) pursuant to which it received an exclusive license to commercialize up to 11 generic topical prescription drug products, including 10 approved products and 1 product pending at the U.S. Food and Drug Administration (FDA), in the United States and its territories. The company sells and distributes generic pharmaceutical products primarily through four sales channels the Global Product sales channel: generic pharmaceutical prescription products it sells directly to wholesalers, large retail drug chains, and others; the Rx Partner sales channel: generic prescription products sold through unrelated third-party pharmaceutical entities pursuant to alliance and collaboration agreements; the Private Label sales channel: generic pharmaceutical over-the-counter (OTC) and prescription products the company sells to unrelated third parties who in-turn sell the product under their own label; and the OTC Partner sales channel: sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical companies pursuant to alliance, collaboration and supply agreements. As of February 6, 2015, the company marketed 96 generic pharmaceutical products representing dosage variations of 29 different pharmaceutical compounds through its Global Division, and 5 other generic pharmaceutical products, representing dosage variations of 2 different pharmaceutical compounds, through its alliance and collaboration agreement partners. As of February 6, 2015, the company’s marketed generic products included authorized generic Adderall XR, fenofibrate (generic to Lofibra), authorized generic Renvela and oxymorphone hydrochloride extended release tablets (AB rated to original OPANA ER). As of February 6, 2015, the company had 21 applications pending at the FDA. Impax Division The Impax Division engages in the development of proprietary brand pharmaceutical products that represent improvements to already-approved pharmaceutical products addressing the treatment of central nervous system (CNS) disorders. The Impax Division also engages in the sale and distribution of branded Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development and Supply Agreement (AZ Agreement) with AstraZeneca UK Limited (AstraZeneca). Each of the Global Division and the Impax Division also generates revenue from research and development services provided to unrelated third-party pharmaceutical entities. The Impax Division is focused on the development and promotion through the company’s specialty sales force of proprietary branded

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPXL:US $49.98 USD +0.12

IPXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPXL.
View Industry Companies
 

Industry Analysis

IPXL

Industry Average

Valuation IPXL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPAX LABORATORIES INC, please visit www.impaxlabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.